Drug Trial Radar · NCT07498647
Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Oct 1, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- BioRay Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, non-befloxacin-controlled, multicenter, phase II clinical trial, evaluating the efficacy, safety, and pharmacokinetic characteristics of BR2251 tablets when administered multiple times in subjects with primary gout and hyperuricemia. This study is a dose exploration study, including a screening period (up to 2 weeks), a double-blind treatment period (12 weeks), and a follow-up period (2 weeks). The screened subjects were stratified based on whether their serum uric acid (sUA) was less than 480 μmol/L or greater than or equal to 480 μmol/L. They were randomly assigned to 4 treatment groups in a 1:1:1:1 ratio: the test drug group 1 (low-dose group), the test drug group 2 (medium-dose group), the test drug group 3 (high-dose group), and the control group (non-befloxacin tablets 40 mg), with 40 subjects in each group. Each group will use titration dosing.
Conditions
- Gout and Hyperuricemia
Interventions
BR2251Drug
BR2251 low dose, mid dose, high dose, Titration regimen and Take orally once a day
FebuxostatDrug
Febuxostat(40mg) Titration regimen and Take orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Uric acidTime frame: Treated to 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.